BioSpace News Archive

NanoSurface Biomedical, a leading provider of biomimetic cell-based assay products and services, announced today that its Chief Science Officer, Dr. Nicholas Geisse, will present at Biotech Showcase 2020 held at the Hilton San Francisco Union Square in San Francisco.

LaVoieHealthScience (LHS), a leading strategic communications firm dedicated to advancing health and science innovation, reported today on the agency’s first annual panel held on December 19 in Cambridge, Massachusetts, entitled, An Unvarnished Look at JPM Week 2020.

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries, announced that Michael Stubblefield, President and Chief Executive Officer, and Tom Szlosek, Executive Vice President, Chief Financial Officer, will participate in the J.P. Morgan Healthcare Conference

EmblemHealth, one of the nation’s largest non-profit health insurers, announced that effective January 1, 2020, it has significantly reduced the number of medical procedures for which members will require prior authorization before receiving care.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2020 meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN), and the American Society for Reconstructive Microsurgery (ASRM).

Ironwood Pharmaceuticals, Inc. will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 4:00 p.m. Pacific Time/ 7:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco.

In accordance with the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million.

The webcast replay will be available one hour after the conclusion of the live presentation and archived for 60 days.

Company to hold conference call Friday, January 3, 2020 at 8:30 am Eastern Time

Combination of CAR-T cell therapy with CARVac highlights the value of cross-platform synergies to address key development challenges in the treatment of cancer